MP-376 is a novel solution formulation of levofloxacin for aerosol administration, being developed for the management of CF patients with chronic infections due to Pseudomonas aeruginosa. Pharmacokinetic studies in animals show that the formulation promotes retention of active drug in the lung which results in enhanced efficacy in animal models of infection compared to other aerosol or systemic formulations of levofloxacin (11). MP-376 is a preservative free, pH 5 -7 and 350 -500 mOsm (slightly hyperosmotic) solution that has been optimized for administration using a customized, investigational, high-efficiency PARI eFlow® nebulizer for rapid delivery using single or twice daily dosage regimens. The purpose of this study was to evaluate and compare the safety, tolerability, pharmacokinetic profile of two formulations of MP-376 (50 and 100 mg/mL) at two dose levels in CF subjects, in order to facilitate the design of further clinical trials of MP-376.
Study Design. This was a multi-center, randomized, single-blind, crossover study of two concentrations of MP-376 (50 mg/mL and 100 mg/mL; 180 mg dose) administered via inhalation using a customized, investigational, PARI eFlow nebulizer, followed by 7 days of daily treatment with a 240 mg (100 mg/mL) dose. After completing the screening procedures, qualified patients were randomized to one of the treatment sequences as shown in Table 1 . Subjects received, in an order specified by a randomization schedule, a single 180 mg dose of one formulation in Period 1 of the study, followed by a 7-day wash-out period and a single 180 mg dose of the other formulation in Period 2. On the days when pharmacokinetic samples were obtained, patients rinsed their mouths and swallowed 15 mL of Maalox ® (400 mg magnesium hydroxide, 400 mg aluminum hydroxide) 5 minutes prior to and 5 minutes after dosing in order in order to minimize oral absorption of any swallowed levofloxacin. This was done so that serum levofloxacin levels would better reflect the intrapulmonary deposition and absorption from the airways. After an additional 7-day wash-out period, the third and final period of the trial consisted of seven consecutive days of once-daily 240 mg dosing using the 100 mg/ml formulation. -1000 ng/ml, with a between-and within-day precision of < 8.0 %. The sputum standard curve was linear from 100 -50,000 ng/ml, with a between-and within-day precision of < 4.0%.
Safety Evaluation.
Patients were seen a total of 9 times during the study; a screening visit, 2 visits around each of the single dose periods, 3 visits during the multiple dose period, and a follow up visit. AEs were collected at each visit. Safety was assessed by evaluating adverse events (AEs), and changes from baseline in physical examinations, vital signs, electrocardiograms, pulse oximetry results, spirometry, and laboratory test results. 
RESULTS
Ten CF subjects enrolled in the study and all subjects completed the study successfully.
Patient characteristics were similar across the two treatment sequences and are shown in Table 2 . The overall mean age was 32.4 years, 60% of the patients were female, all
were Caucasian and there were no clinically relevant differences in medical history or screening physical examination findings. The average baseline percent predicted FEV 1 for all patients was 67.1%, with similar mean baseline FEV1 values in each treatment sequence.
Pharmacokinetics. Serum. The mean serum levofloxacin concentrations for all three doses are shown in Figure 1 . A comparison of the mean serum and sputum exposures are shown in Figure   2 . After administration of 180 mg MP-376, the mean Cmax and AUC(0-inf) for the 100 mg/mL formulation were 35% and 22% higher than the corresponding values for the 50 mg/mL formulation, respectively (Table 3) , but the differences were not statistically signficant. There was a 1.33-fold increase in the mean Cmax after administration of 240 mg versus 180 mg as the 100 mg/mL formulation, exactly proportional to the Sputum. Sputum pharmacokinetic parameters are shown in Table 4 . Inhalation of a 180 mg dose as either the 50 or 100 mg/ml formulation resulted in similar mean sputum levofloxacin Cmax and AUC (Table 4 ). After 7-days of 240 mg per day dosing with the 100 mg/ml formulation, increases in Cmax and AUC were both slightly higher than dose proportional (1.6-fold and 2.3-fold increase, respectively, versus a dose increase of 1.33-fold). The mean t½ was comparable for all three doses, ranging from 3.55 h to 4.58 h (Table 3) .
Safety. MP-376 was very well tolerated with both concentrations and doses. A total of
26 AEs were reported by 7 of the 10 patients during the study. The number of patients reporting an AE was similar across each treatment period (60%, 50%, and 40% for periods 1, 2, and 3, respectively). Adverse events that were reported in 2 or more patients are as follows: Dysgeusia was noted in 4/10 patients with the 180 mg single dose (50 mg/ml), 4/10 with the 180mg single dose (100 mg/ml), and 4/10 during the 240 mg multiple dose (100 mg/ml) period. Hemoptysis occurred in 1/10 patients with the 180mg single dose (50 mg/ml) and 1/10 patients with the 180mg single dose (100mg/ml). No patients experienced hemoptysis during the multiple dose period. Of the 26 AEs, 25 were mild and one was moderate. The moderate AE was back pain and was judged not to be related to study drug. Nineteen events in 4 patients were considered related to study drug (either possibly or probably). A similar AE profile, with respect to event, severity, and relationship, was observed across treatment periods. No patient experienced a serious adverse event and no patient discontinued the study due For CF patients who spend considerable time taking their prescribed daily inhaled medications, it is important to consider the treatment burden when developing new therapies. This pharmacokinetic study showed that the 100 mg/mL formulation of MP-376 produced serum and sputum levels of levofloxacin that were similar to the 50 mg/mL formulation and required less time for nebulization.
After 7 days of 240 mg daily dosing using the 100 mg/mL formulation, the serum and sputum exposures were approximately dose-proportional with the 180 mg dose with regard to Cmax, and seemed higher than dose-proportional with regard to AUC values. 
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